Scroll down to our Events Calendar and register now for free

Integrate Powerful Hemp Cannabinoids into your Healthcare Practice

Learn from leading cannabis clinician Bonni Goldstein, MD and grow your practice revenues through our lab-tested hemp extract marketplace, while providing an exclusive medical discount to your patients. For a limited time, our platform is free for licensed US healthcare practitioners only.

BOOK A DEMO GET STARTED

Are you a patient? Click here to find a practitioner

Learn

Learn from leading cannabis clinician Bonni Goldstein, MD. Our free curriculum and certificate course include the latest research, evidence-based videos and webinars, forums, and powerful tools for tailoring patient-specific cannabinoid regimens.

JOIN NOW

Heal

Accelerate positive patient outcomes with our proprietary cannabinoid regimen algorithms for over 20 conditions, including pain, sleep and anxiety.

JOIN NOW

Grow

Grow your practice revenues by recommending lab-tested, professional-grade hemp cannabinoid products from our marketplace, with an exclusive medical discount for your patients.

JOIN NOW

Free Account Exclusively for Licensed US Healthcare Practitioners

Comprehensive evidence-based curriculum and Advanced Practitioner Certificate Course for medical hemp and cannabis therapies
Full access to our lab-tested, HIPAA-compliant marketplace with practitioner revenue sharing and patient discounts
Live webinars and mentoring sessions
Access our cannabinoid regimen algorithm for three conditions
Unlock all 24 conditions after account qualification

GET STARTED

Are you a patient looking for a medical cannabis practitioner? Click here to find a practitioner

Image of patient looking at screen with a practitioner

Did you know that Endocannabinoid System Deficiency is linked to many chronic and intractable conditions?

Our professional curriculum and curated marketplace are built upon Dr. Goldstein’s 35 years of clinical experience, serving over 20,000 medical cannabis patients with a broad range of conditions including chronic pain, insomnia, anxiety, and more.

LEARN MORE

Gastrointestinal Disorders

Inflammatory Pain

Insomnia

Menopause

Menstrual Pain / Endometriosis

Opioid / Substance Dependence

Traumatic Brain Injury

Image of a practitioner writing on a clipboard

Dosing Regimens

Use the Goldstein Wellness Cannabinoid Regimen algorithms to accelerate your path to clinical success.

Join to learn more about cannabinoid-based medicine for these conditions and more

GET STARTED

Cannabinoids and Autism Spectrum Disorder

Learn more

Cannabinoids and Fibromyalgia

Learn more

THC Tolerance

Learn more

Cannabinoids and PTSD

Learn more

Cannabinoids for Sleep

Learn more

Cannabinoids and Neurodegenerative Disorders

Learn more

Image of a practitioner pointing to medicine

Trusted Products

The hemp industry is confusing. Healthcare professionals and their patients need access to safe, lab-tested products. Our trusted vendors have supplied Dr. Goldstein’s practice for over a decade with effective, professional-grade products.

VIEW OUR CATALOG

Internationally recognized expert on medical cannabis

With over 30 years of unwavering commitment to her patients, Bonni Goldstein MD has tirelessly cared for those who struggle with refractory conditions, offering hope and compassion.

As a staunch advocate for medical cannabis, she champions this natural treatment as it is not only safe and well-tolerated, but also consistently demonstrates efficacy in improving patients’ quality of life. Through her extensive experience and dedication, she continues to fight for quality products and patient access, ensuring that every patient receives the personalized care they deserve.

READ DR. BONNI'S FULL BIOGRAPHY

Check out Dr. Goldstein’s ground-breaking research published in Nature – Scientific Reports

The study analyzes how children with autism spectrum disorder (ASD) respond metabolically to medical cannabis treatment using an innovative saliva test. The research employs a machine learning-based analysis of metabolomics data to uncover patterns and potential biomarkers that could help tailor cannabis treatments for ASD. This approach highlights the potential for personalized medicine in treating ASD using cannabinoids. For over 16 years, Dr. Goldstein has designed personalized cannabinoid regimens for patients across a broad range of chronic and acute conditions.

READ ARTICLE

Our daughter was born with a severe seizure disorder and after many failed drug therapies, we decided to try cannabis.

In the first year we saw a 70% reduction in seizures (no pill ever gave that kind of relief to her) and we saw an amazing improvement in her overall health. The only regret we have about cannabis is not using it first. Today she’s almost 13 and has an 85% reduction in seizures... Read more...

- K.B. (mother)

I completed the Goldstein Wellness certification course and loved it! I'm now going through it again because it is so informational.

Love your content, thank you for sharing such wonderful information!

- Dr. Sarah S

I have been fortunate to be a patient of Dr. Bonni Goldstein. She is a well known author and mentor to many physicians worldwide.

I have severe bone-on-bone knee osteoarthritis and every step I took was painful. Through Dr. Goldstein’s expertise I started CBDA treatment and now I can walk without pain... Read more...

- I.B. (patient)

Dr. Bonni Goldstein's medical cannabis education course has been pivotal in refining my clinical approach to prescribing medical cannabis. This well-structured, comprehensive program provides an essential foundation, ensuring that healthcare providers can practice cannabis medicine safely and effectively... Read more...

- Irma Velasco, MSN, APRN, FNP-BC

Cannabinoids have been lifesaving for Sadie.

I know we're never really out of the woods but she hasn't had a seizure since August, she sleeps 12-15 hours/night, and she is the happiest and most social we've ever seen her, thanks in large part to Dr. Goldstein’s care.

- S.B. (mother)

I was lucky enough to have Dr. Goldstein as a mentor. Not only is she the top pediatric cannabis physician in the country, she is an exemplary teacher too.

I have taken most of her courses and attended a number of her lectures. Her many years of clinical practice and research add a very valuable insight. I highly recommend taking her courses or going to any conference where she has been invited to speak.

- Leigh Vinocur MD, MS

Image of a practitioner speaking to a patient

FAQ about Medical Hemp and Cannabis

Why don’t medical schools teach about the endocannabinoid system (ECS)?

Why are there so few randomized placebo-controlled trials on the benefits of medical hemp and cannabis?

What evidence is there that cannabinoids positively affect human health? Isn’t it all just anecdotal?

The ECS is one of the most extensive neuromodulatory systems in the body with dozens of critical target receptors and its dysfunction has been linked to many chronic conditions
There are several landmark publications and hundreds of peer-reviewed published studies and reviews providing evidence across many conditions:
- The 2017 National Academy of Sciences, Engineering and Medicine Report on The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research documented conclusive evidence of benefits of cannabis for chronic pain, chemotherapy-induced nausea and vomiting and spasticity due to multiple sclerosis (Abrams, Donald I. “The therapeutic effects of Cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report.” European journal of internal medicine 49 (2018): 7-11.)
- Clinical Endocannabinoid Deficiency was posited by Ethan Russo, MD, in 20024 and subsequently has been supported by ongoing research (Russo, Ethan B. “Clinical endocannabinoid deficiency (CECD).” Neuroendocrinology Letters 29.2 (2008); Smith, Steele Clarke, and Mark S. Wagner. “Clinical endocannabinoid deficiency (CECD) revisited.” Neuroendocrinology Letters 35.3 (2014); Russo, Ethan B. “Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes.” Cannabis and cannabinoid research 1.1 (2016): 154-165.)
- Multiple published surveys and reviews document the benefits of cannabinoids for an array of conditions, including chronic pain (Sexton, Michelle, et al. “A cross-sectional survey of medical cannabis users: patterns of use and perceived efficacy.” Cannabis and cannabinoid research 1.1 (2016): 131-138; O’Brien, Kylie, et al. “Overview of medicinal cannabis.” medicinal cannabis and CBD in mental healthcare (2021): 89-129; Baratta, F., et al. “Cannabis for medical use: Analysis of recent clinical trials in view of current legislation.” Frontiers in Pharmacology 13 (2022): 888903; Russo, Ethan B. “Cannabis therapeutics and the future of neurology.” Frontiers in integrative neuroscience 12 (2018): 413977; Harris, Michael, et al. “UK Medical Cannabis registry: an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions.” Expert review of clinical pharmacology 15.4 (2022): 473-485.)

Collapse

What are some typical conditions that may respond to cannabinoids?

Is there a risk of addiction, schizophrenia or psychosis?

The risk of cannabis addiction in recreational users of THC-dominant cannabis is estimated to be about 9% per the National Institute of Drug Abuse (NIDA), compared to alcohol (10%), cocaine (15%), tobacco (32%), and heroin (23%).
There is no evidence of cannabis addiction with medically supervised use of cannabinoids for medical purposes when minimal effective dosing is employed (Sagar, Kelly A., et al. “Assessing cannabis use disorder in medical cannabis patients: interim analyses from an observational, longitudinal study.” Cannabis 4.2 (2021): 47.)
There is some evidence of increased risk of schizophrenia/psychosis in one particular situation, namely non-medical use of high-dose THC in young teenagers who have genetic predisposition for severe mental illness, especially in a first degree relative (Zammit, Stanley, et al. “Does cannabis use cause schizophrenia? The epidemiological evidence.” Marijuana and madness (2012): 169-183; Marconi, Arianna, et al. “Meta-analysis of the association between the level of cannabis use and risk of psychosis.” Schizophrenia bulletin 42.5 (2016): 1262-1269.)
There is no evidence of increased risk of schizophrenia with medically supervised therapeutic cannabinoid use
Cannabidiol (CBD) has well-documented antipsychotic properties and should be included in the regimen if there are any concerns of potential psychosis with THC, for example, in patients with previous serious mental health issues (Iseger, Tabitha A., and Matthijs G. Bossong. “A systematic review of the antipsychotic properties of cannabidiol in humans.” Schizophrenia research 162.1-3 (2015): 153-161; Seeman, P. “Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose.” Translational psychiatry 6.10 (2016): e920-e920.)
Unsupervised overuse of THC-rich cannabis can not and should not be compared to medically supervised, appropriately dosed cannabinoid use intended for therapeutic outcomes
THC warrants caution due to impairment, but can be easily and safely managed with “start low and go slow” appropriate medical dosing
Non-impairing hemp-derived cannabinoids, such as CBD, CBG, and CBDA, are safe and well-tolerated under medical supervision that includes consideration of cannabinoid-drug interactions